Indian stocks: Visit www.stage2stocks.com →

IRulya Therapeutics Inc.

Stage 2 · Advancing · week 2

As of Oct 22, 2026, IRulya Therapeutics is in Stage 2, the uptrend phase, now in week 2 (since Oct 12, 2026). It closed at $32.83, 73.1% below its 52-week high and above its 200-day average, which is falling.

IRulya Therapeutics Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. More about the company

$32.83
-5.33% today
$33.4M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care

Is IRLA early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 14w
S4 23w
S2 17w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S3 6w → S4 14w → S1 7w → S2 5w → S3 2w → S4 23w → S1 7w → S2 13w → S3 12w → S4 7w → S1 5w → S2 8w → S3 3w → S2 17w → S3 4w → S4 10w → S1 3w → S4 8w → S1 8w → S2 2w current
Total tracked: 165 weeks across 20 stage runs.

IRLA among Biotechnology214th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…214IRLAStage 2 · wk 247+8.9%
vs 52W High
-73.1%
$5.40 lo$122.00 hi
73.1% below 52W high
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 2
1w13w26w
Week 2, fresh breakout
How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.
vs 200 DMA
13.3%
200 DMA: $28.97 · sloping down
Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.
Rel Volume
4.46x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↑
Short-term trend rising strongly
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
+8.9%
3M
+83.9%
6M
+20.7%
YTD
-45.3%
1Y
-9.8%
Scan Membership
Breakout Watch
Latest: 2024-11-12
7 appearances in last 60 days. First seen: 2020-02-24.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S2
Wk 2 · Vol 4.46x
2026-10-21S2
Wk 2 · Vol 6.28x
2026-10-20S2
Wk 2 · Vol 11.31x
2026-10-19S2
Wk 2 · Vol 1.50x
2026-10-16S2
Wk 1 · Vol 0.41x
2026-10-15S2
Wk 1 · Vol 0.31x
2026-10-14S2
Wk 1 · Vol 0.93x
2026-10-13S2
Wk 1 · Vol 2.99x
2026-10-12S21→2
Wk 1 · Vol 2.81x
2026-10-09S1
Wk 9 · Vol 5.39x
2026-10-08S1
Wk 8 · Vol 1.19x
2026-10-07S1
Wk 8 · Vol 0.47x
Moving averages & range
50 DMA
$31.18
200 DMA
$28.97
52W High
$122.00
52W Low
$5.40
5D Low
$32.03
Resistance levels (recent highs)
20d High
$40.27
60d High
$40.27
120d High
$40.27
250d High
$122.00
Next resistance
+22.7%
to 20d High
ROE
-153.8%
Profit margin 0.0%
Dividend Yield
0.00%
P/B -0.9

IRulya Therapeutics: quick answers

What stage is IRulya Therapeutics in?

As of Oct 22, 2026, IRulya Therapeutics (IRLA) is in Stage 2, the uptrend phase. It entered Stage 2 on Oct 12, 2026 and is in week 2. What the four stages mean

Is IRulya Therapeutics in an uptrend?

Yes. IRulya Therapeutics is in a Stage 2 uptrend. It trades 13.3% above its 200-day average, which is falling.

How far is IRulya Therapeutics from its 52-week high?

IRulya Therapeutics closed at $32.83 on Oct 22, 2026, 73.1% below its 52-week high of $122.00. Its 52-week low is $5.40.

How has IRulya Therapeutics performed over the past year?

As of Oct 22, 2026, IRulya Therapeutics is down 9.8% over the past year and down 45.3% so far in 2026.

Which sector and industry is IRulya Therapeutics in?

IRulya Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

IRulya Therapeutics Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidate comprises eDSP, which is in Phase 3 for the treatment of rare pediatric neurodegenerative diseases, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in the ATM gene. Its AIDE technology platform is a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells and consists of automated equipment, the RCL, a sterile single-use consumable treatment kit comprising medical device kits, syringe kits, and process solutions. IRulya Therapeutics Inc. was formerly known as Quince Therapeutics, Inc. and changed its name to IRulya Therapeutics Inc. in October 2026. The company was incorporated in 2012 and is headquartered in New Haven, Connecticut.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.